HRYZ-T101 Injection for HPV18 Positive Solid Tumor
A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor. The study will investigate RP2D of HRYZ-T101 TCR-T cell injection.
Cervical Cancer|Head and Neck Squamous Cell Carcinoma|Carcinoma of Vagina|Carcinoma of Penis|Anal Cancer|Carcinoma of Vulva
BIOLOGICAL: HRYZ-T101 Injection|DRUG: Fludarabine + Cyclophosphamide
DLT, Dose-limiting toxicity, 28 days|Adverse events and serious adverse events, Incidence of adverse events and serious adverse events, 2 years
Objective Response Rate（ORR）, The percentage of subjects with PR or CR assessed by RECIST 1.1., 2 years|Disease Control Rate (DCR), The percentage of subjects with a confirmed CR, PR, or stable disease (SD) assessed by RECIST 1.1., 2 years|Duration of response (DoR), Subjects who show a confirmed CR or PR as assessed by RECIST 1.1., 2 years|Time to response (TTR), Time from date of T-cell administration to first documented evidence of confirmed (CR or PR) as assessed by RECIST 1.1., 2 years|Progression-Free Survival（PFS）, The length of time from enrollment until the time of progression of disease., 2 years|Overall Survival (OS), The interval of time between the date of T-cell infusion and the date of death., 2 years|Duration of TCR T cells in-vivo persistence, Blood samples were collected to measure persistence of infused HRYZ-T101., 2 years|Concentration of Cytokines (IL-2、IL-6、IL-10、TNFα、IFNγ), Collect blood samples and analyze for presence of cytokines (IL-2、IL-6、IL-10、TNFα、IFNγ) at specified intervals before and after treatment with HRYZ-T101., 2 years
Number of Subjects with positive anti-drug antibodies (ADA), Serum samples will be collected to analyze for the presence of ADAs using validated immunoassays., 2 years|Number of subjects with replication competent lentivirus (RCL), RCL exposure will be assessed by polymerase chain reaction (PCR) based assay., 2 years|T cell subgroup in peripheral blood, Collect blood samples and analyze for T cell subgroup by flow cytometry at specified intervals before and after treatment with HRYZ-T101., 2 years
A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor. The study will investigate RP2D of HRYZ-T101 TCR-T cell injection.